MARKET

SLS

SLS

Sellas Life Sciences Group Inc
NASDAQ
1.375
-0.025
-1.79%
Opening 11:22 05/28 EDT
OPEN
1.390
PREV CLOSE
1.400
HIGH
1.410
LOW
1.355
VOLUME
212.91K
TURNOVER
0
52 WEEK HIGH
1.914
52 WEEK LOW
0.4986
MARKET CAP
79.41M
P/E (TTM)
-1.2319
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at SLS last week (0520-0524)?
Weekly Report · 1d ago
Solaris Resources announces $35 million bought deal offering
Solaris Resources announces $35 million bought deal offering May 21, 2024. Life Sciences Group, Inc. (SLS) Stock. Solaris Resources announced $35M bought deal sale of 7,150,000 common shares for gross proceeds of approximately $35m.
Seeking Alpha · 6d ago
Weekly Report: what happened at SLS last week (0513-0517)?
Weekly Report · 05/20 09:58
Strong Buy Rating on SELLAS Life Sciences Amid Progress in AML Treatment Pipeline
TipRanks · 05/17 18:05
SLS Stock Earnings: SELLAS Life Sciences Gr Misses EPS for Q1 2024
Investorplace · 05/15 02:54
SELLAS Life Sciences Group, Inc. - Quarterly Report for the Quarter Ended March 31, 2024
Press release · 05/15 01:19
SELLAS Life Sciences GAAP EPS of -$0.21
SELLAS Life Sciences Group, Inc. Reports Q1 GAAP EPS of -$ as of March 31, 2024. As of May 14, 2024, cash and cash equivalents totaled approximately $ million. The company expects to post a GAAP quarterly loss of $0.05.
Seeking Alpha · 05/14 20:58
SELLAS Life Sciences Gr Q1 2024 Adj EPS $(0.21) Misses $(0.16) Estimate
Benzinga · 05/14 20:35
More
About SLS
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of novel therapeutics for a range of cancer indications. The Company's product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor. GPS is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.

Webull offers Sellas Life Sciences Group Inc stock information, including NASDAQ: SLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLS stock methods without spending real money on the virtual paper trading platform.